In short
Calcium levofolinate, also known as levofolinic acid, is a drug being studied in various clinical trials for its potential to enhance the effectiveness of cancer treatments. This article explores how calcium levofolinate is being used in combination with other drugs to treat different types of cancer, including pancreatic, colorectal, and gastric cancers.
At a glance
- Drug Combinations
- Calcium levofolinate is studied in combination with 5-FU, oxaliplatin, irinotecan, and other drugs
- Cancer Types
- Pancreatic cancer, colorectal cancer, advanced gastric cancer
- Administration
- Intravenous infusion, typically as part of chemotherapy regimens
- Primary Outcomes
- Progression-free survival, overall survival, safety and tolerability
- Secondary Outcomes
- Objective response rate, quality of life, pharmacokinetics
- Trial Phases
- Phase II and Phase III studies are ongoing
- Treatment Duration
- Varies by trial, often until disease progression or unacceptable toxicity
What is Calcium Levofolinate?
Calcium levofolinate, also known as levofolinic acid, is a medication used in cancer treatment. It is a form of folic acid, a vitamin that plays a crucial role in cell growth and division. In cancer therapy, calcium levofolinate is often used to enhance the effectiveness of other chemotherapy drugs.
Uses of Calcium Levofolinate
Calcium levofolinate is primarily used in the treatment of various types of cancer, including:
- Colorectal Cancer: It is used in the treatment of metastatic colorectal cancer (cancer that has spread from the colon or rectum to other parts of the body).
- Pancreatic Cancer: Calcium levofolinate is used in the treatment of pancreatic ductal adenocarcinoma, a type of pancreatic cancer.
- Gastric Cancer: It is also used in the treatment of advanced gastric cancer (cancer of the stomach) and adenocarcinoma of the esophagogastric junction (cancer where the esophagus meets the stomach).
Combination Therapies
Calcium levofolinate is rarely used alone. Instead, it is typically combined with other chemotherapy drugs to create more effective treatment regimens. Some common combinations include:
- FOLFIRI: This regimen combines calcium levofolinate with fluorouracil (5-FU) and irinotecan.
- FOLFOX: In this combination, calcium levofolinate is used with fluorouracil and oxaliplatin.
- mFOLFIRINOX: This is a modified version of FOLFIRINOX, which includes calcium levofolinate, fluorouracil, irinotecan, and oxaliplatin.
These combinations are designed to attack cancer cells in multiple ways, potentially increasing the effectiveness of the treatment.
How is Calcium Levofolinate Administered?
Calcium levofolinate is typically administered intravenously (through a vein) in a hospital or clinic setting. The dosage and frequency can vary depending on the specific treatment regimen and the patient's individual needs. For example:
- In some regimens, it may be given at a dose of 200 mg/m² every 14 days.
- In others, it might be administered at 100 mg/m² on the first day of each 14-day cycle.
The administration is usually part of a larger chemotherapy session that includes other drugs.
Potential Side Effects
While calcium levofolinate itself is generally well-tolerated, patients may experience side effects from the combination chemotherapy regimens it's used in. These can include:
- Nausea and vomiting
- Diarrhea
- Fatigue
- Decreased blood cell counts, which can increase the risk of infection or bleeding
- Hair loss
It's important to discuss potential side effects with your healthcare provider, as they can provide guidance on managing these symptoms.
Ongoing Research
Calcium levofolinate continues to be studied in various clinical trials to improve cancer treatment outcomes. Researchers are investigating its use in different combinations and for various types of cancer. For example:
- A study is looking at combining calcium levofolinate-based chemotherapy with a new drug called NP137 for pancreatic cancer.
- Another trial is comparing different calcium levofolinate-containing regimens (mFOLFOX, mFOLFIRI, and FOLFPTX) for gastric cancer.
These ongoing studies aim to find more effective ways to use calcium levofolinate in cancer treatment, potentially leading to better outcomes for patients in the future.